Login to Your Account



Depomed, Esprit Enter $50M Deal To Market Proquin XR

By Randall Osborne


Friday, July 29, 2005
After sifting through would-be licensors, Depomed Inc. is entering a $50 million deal with Esprit Pharma Inc. to market and distribute Proquin XR, the extended-release form of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription